Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Homeostatic Imbalance01:10

Homeostatic Imbalance

31.7K
Homeostasis is the maintenance of a stable internal environment within the body, which is crucial for the proper functioning of cells, tissues, organs, and organ systems. The body has various control mechanisms that work together to regulate various physiological parameters such as temperature, blood pressure, pH balance, and fluid balance, to name a few. These control mechanisms are based on feedback loops that can be either positive or negative.
However, sometimes these feedback loops fail,...
31.7K
Hemoglobin01:24

Hemoglobin

7.1K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
7.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Hematopoiesis01:21

Hematopoiesis

8.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies.

British journal of haematology·2026
Same author

Structural variant discovery and diagnostic impact in rare diseases from short-read and long-read sequencing.

medRxiv : the preprint server for health sciences·2026
Same author

RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.

medRxiv : the preprint server for health sciences·2026
Same author

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.

Science advances·2026
Same author

Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.

Cell·2026
Same author

Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.

bioRxiv : the preprint server for biology·2026

関連する実験動画

Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K

HIFを安定させ,貧血を緩和する

Richard A Voit1, Vijay G Sankaran1

  • 1Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Cell
|January 18, 2020
PubMed
まとめ

RoxadustatはHIF- プロリル水酸化酵素 (HIF- PHD) を阻害し,貧血の治療のためにエリトロポエチン (EPO) を強化する. これは慢性腎臓病患者の鉄吸収と貧血を改善します.

科学分野:

  • 腎臓科
  • 分子生物学
  • 薬理学について

背景:

  • 腎臓疾患の貧血は,エリトロポエチン (EPO) 産生障害と関連しています.
  • 低酸素誘導因子1-α (HIF-1α) はEPOを調節する.
  • HIF-プロリルヒドロキシラーゼ (HIF-PHD) は,通常の酸素濃度下でHIF-1αを分解する.

研究 の 目的:

  • HIF-PHDに対するロクサダスタットの効果を調査する.
  • EPOの生成と鉄の吸収に対するロクサダスタットの影響を評価する.
  • 慢性腎臓病 (CKD) の貧血の治療におけるロクサダスタットの有効性を評価する.

主な方法:

  • HIF- PHD酵素の活性抑制
  • エリトロポエチン (EPO) 濃度のモニタリング
  • 鉄の吸収パラメータの評価
  • 慢性腎臓病患者の貧血の臨床評価

主要な成果:

  • RoxadustatはHIF- PHDを効果的に抑制する.
  • 抑制により,EPOの生成が増加します.
  • 慢性腎臓病患者の鉄吸収の改善と貧血の改善が観察されました.

さらに関連する動画

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K

関連する実験動画

Last Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K

結論:

  • RoxadustatはCKDにおける貧血に対する有望な治療薬である.
  • HIF-PHDの抑制は腎臓病性貧血の管理に有効な戦略です.
  • Roxadustatは,赤色形成と鉄の恒常性を高めるための新しいアプローチを提供します.